Results 101 to 110 of about 106,721 (360)

Association of ulcerative colitis, celiac disease, primary sclerosing cholangitis and liver cirrhosis in a young male

JGH Open, 2023
Inflammatory bowel diseases (IBD), including ulcerative colitis, are chronic autoimmune conditions characterized by inflammation of the digestive system.
Ahmad N. Alkhaledi, Isra Jadaan, Mohamad Zaher Sharfo, Tala Faysal, Yazane Abdallah, Ahmad Alhaj Ali   +5 more
doaj   +1 more source

Tacrolimus (FK 506), a Treatment for Primary Sclerosing Cholangitis: Results of an Open‐Label Preliminary Trial [PDF]

, 1995
Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the liver that is characterized by progressive cholestasis and the development of secondary biliary cirrhosis. There is no widely recognized therapy for this disease, although anti‐
Abu‐Elmagd, K, Carroll, P, Irish, W, McMichael, J, Rodriguez‐Rilo, H, Starzl, TE, Van Thiel, DH   +6 more
core   +1 more source

Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis

Hepatology, 2020
Many children with primary sclerosing cholangitis (PSC) receive oral vancomycin therapy (OVT) or ursodeoxycholic acid (UDCA). There is a paucity of data on whether these medications improve outcomes.
M. Deneau, C. Mack, D. Mogul, E. Perito, P. Valentino, A. Amir, Matthew DiGuglielmo, L. Draijer, W. El-Matary, K. Furuya, N. Gupta, Jessica T. Hochberg, S. Horslen, M. K. Jensen, M. Jonas, N. Kerkar, B. Koot, Trevor J. Laborda, Christine K. Lee, K. Loomes, Mercedes Martinez, A. Miethke, T. Miloh, S. Mohammad, N. Ovchinsky, Girish S Rao, A. Ricciuto, P. Sathya, K. Schwarz, U. Shah, Ruchi Singh, Bernadette E Vitola, A. Zizzo, S. Guthery   +33 more
semanticscholar   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source

NISCH syndrome with hypothyroxinemia

Annals of Hepatology, 2010
Neonatal Ichthyosis Sclerosing Cholangitis (NISCH) syndrome is a rare autosomal recessive condition characterized by ichthyosis, sclerosing cholangitis and alopecia. Only 5 patients have been described till now.
Ira Shah, Susmita Bhatnagar
doaj   +1 more source

Primary sclerosing cholangitis

Annual Review of Medicine, 1993
Primary sclerosing cholangitis (PSC) is an inflammatory disease of unknown etiology. It affects the biliary system and is characterized by fibrosis and progressive obliteration of extrahepatic and intrahepatic bile ducts. Its frequent coexistence with antibody-mediated diseases, certain human leukocyte antigens, and altered lymphocyte mechanisms ...
openaire   +2 more sources

Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Extraintestinal manifestations (EIMs) manifest in 6%‐47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged
Giulia D'Arcangelo, Dan Turner, Oren Ledder, Esther Orlanski‐Meyer, Efrat Broide, Maya Granot, Manar Matar, Seamus Hussey, Anat Yerushalmy‐Feler, Christoph Norden, Erasmo Miele, Marina Aloi   +11 more
wiley   +1 more source

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis

Gut and Liver, 2019
Sclerosing cholangitis (SC) is defined as a condition with progressive stenosis and destruction of the bile ducts due to diffuse inflammation and fibrosis and currently includes three categories: primary sclerosing cholangitis (PSC), secondary ...
Atsushi Tanaka
doaj   +1 more source

Alterations of the bile microbiome in primary sclerosing cholangitis

Gut, 2019
Background Patients with primary sclerosing cholangitis (PSC) display an altered colonic microbiome compared with healthy controls. However, little is known on the bile duct microbiome and its interplay with bile acid metabolism in PSC.
T. Liwinski, R. Zenouzi, C. John, H. Ehlken, M. Rühlemann, C. Bang, S. Groth, W. Lieb, M. Kantowski, Nils Andersen, G. Schachschal, T. Karlsen, J. Hov, T. Rösch, A. Lohse, J. Heeren, A. Franke, C. Schramm   +17 more
semanticscholar   +1 more source

Hepatopulmonary syndrome in children and adolescents with portal hypertension in Brazil: A multicenter study

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives To describe the clinical and laboratory characteristics and outcomes of pediatric hepatopulmonary syndrome (HPS) secondary to portal hypertension (PH) in Brazil. Methods Fifty‐four pediatric patients diagnosed with PH and HPS according to the European Respiratory Society criteria were included in this multicenter retrospective study.
Leticia Drumond Alberto, Eleonora Druve Tavares Fagundes, Adriana Teixeira Rodrigues, Thaís Costa Nascentes Queiroz, Gustavo Valverde de Castro, Carlos Oscar Kieling, Sandra Maria Gonçalves Vieira, Natália Lamounier dos Martires Guerra, Natascha Silva Sandy, Gilda Porta, Irene Kazue Miura, Maria Ângela Bellomo Brandão, Gabriel Hessel, Adriana Maria Alves de Tommaso, Alexandre Rodrigues Ferreira   +14 more
wiley   +1 more source